<SEC-DOCUMENT>0001193125-22-302722.txt : 20221212
<SEC-HEADER>0001193125-22-302722.hdr.sgml : 20221212
<ACCEPTANCE-DATETIME>20221212160149
ACCESSION NUMBER:		0001193125-22-302722
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221212
FILED AS OF DATE:		20221212
DATE AS OF CHANGE:		20221212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		221457129

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d381511d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 12, 2022, Kazia Therapeutics Limited (the &#147;Company&#148;) issued an ASX Announcement titled &#147;Kazia Announces
Receipt of Nasdaq Minimum Bid Notification.&#148; A copy of this release is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit&nbsp;99.1 into the Company&#146;s
registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d381511dex991.htm">Announcement of Kazia Therapeutics Limited dated December 12, 2022 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 12&nbsp;December 2022</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d381511dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g381511dsp3a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12&nbsp;December 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney</B><B>, </B><B>12 D</B><B>ecember</B><B> 2022</B> &#150; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) received a deficiency notification from
the Listing Qualifications Staff of the Nasdaq Stock Market LLC, dated December&nbsp;9, 2022, notifying the company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Capital Market&#146;s rules for continued
listing (the &#147;Notice&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deficiency notification has no immediate impact on the company&#146;s operations or listing. Kazia&#146;s
securities will continue to trade as normal on Nasdaq-CM under the ticker KZIA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a
minimum bid price of at least US$&nbsp;1.00 per share, and failure to do so for a period of 30 consecutive business days triggers a deficiency notice. Based on the closing bid price of Kazia&#146;s American Depository Shares, each representing ten
ordinary shares of the company (ADSs), for the period from October&nbsp;27, 2022 to December&nbsp;8, 2022, the company no longer met this requirement as of December&nbsp;8, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days from the date of the Notice, or until June&nbsp;7, 2023, to regain compliance,
during which time the company&#146;s securities will continue to trade as normal on Nasdaq-CM. If at any time before June&nbsp;7, 2023, the bid price of the company&#146;s ADSs closes at or above US$&nbsp;1.00 per share for a minimum of 10
consecutive business days, the company will regain compliance with the minimum bid requirement. If the company does not regain compliance during this period, it may be eligible, upon satisfaction of certain Nasdaq requirements, for an additional
period of 180 calendar days to regain compliance or its securities may be subject to delisting from Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company will closely monitor the
situation and intends to resolve the deficiency and regain compliance with the Nasdaq Listing Rules. The deficiency notice has no impact on the company&#146;s listing on the Australian Securities Exchange (ASX), where it continues to trade as normal
under the ticker KZA. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and an important study for registration,
GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in
August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, and Kazia&#146;s strategy and plans with respect to its programs, including paxalisib. Such statements are based on Kazia&#146;s expectations and
projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including
risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and the related to the impact of global economic conditions. These and other risks and uncertainties are described
more fully in Kazia&#146;s Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g381511dsp3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g381511dsp3a.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * %1'D<)
M&I=SP%49)H2OL)M)78Z6"6"3RYHGC?\ NNI!IM-:,(R4E=,=-:W%N%,\$D0;
M[N]2,_G0XM;H49QE\+N14B@H * "@ H * "@ H * "@ H * "@ H * "@ H
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M#AAZTU)/03BT8M42% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % &WX:TNUU.[E6Y)*QKD(#C=6U&"F]3CQ=:5**<2VWV/PUXG! 9X#'TZF//
M_P"K\C5^[2J&:Y\50\_S(]9UVUN]6LKB"(O';-DEA@OR#C]*52JI2370=##S
MA3E&3W)O$.OV6I6$=O;ABQ<,69<;:=6K&<;(G"X:=*;E(FU7PYI]GHC7$3L)
M8U!#ELA_PJJE&,871%'%5)U>5['(UR'J!0 4 % !0 4 % !0 >PH * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M61X)72<X4 >E?!_P]]NUF;69TS#9#;'D<&0C^@_F*RJ2LK&M-:W,+XC>'O\
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 /,TK6Z0%R8D8NJ=@2 "?\
MQT?E0 R@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M3G^R!IWRJ^>?E7H!T[#%:*<4K&3A)NYYE+$T,SQ/PR,5/U%;&19TK_D,6/\
MUW3_ -"%)[#6Y[G\7?\ D17_ .OB/^M<]/XC>I\)X#72<YWOPH\/?VKXF_M"
M9,VVG@2<C@R'[H_#D_@*RJ.RL:4U=W/6O$,OA34!_9VNWMD?)8.89;G85.."
M0".Q_6L8\RU1L^5Z,LZ,WA^736TK2+BUGM(D*M#%,) JMG@\DX/-#O>[&K;(
M^=_%.AOX=\1WFFMG9&^8F/\ $AY4_E^M=,7=7.:2L[&/5$A0 4 % !0 4 %
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MN*L<[J%]+J6I7-].%$MQ*TKA1@ DY.*I*RL2W=W.PL/BQXBL-/AL]MI.L2;
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M:7,ZF2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVMQ4TUC:K/+<0P"0$QK(3EP/H./QH4-+MB=5*7*DV(=/9+!+MYHD#@E$.=S
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 *CO&X>-V1AT*G!%"=MA-)JS+FFZG-IM^+M1YC8(8,?O ^]7";A*
MYE5HJK#D+6I>()]0O;>X6-8OLYW(N<\Y!Y_(54ZKDT^QG2PT:<7&][DFK>))
MM4LUMC L2Y!8@YSC^5.I6<U8FAA(T9<U[F,9'9 A=B@Z*3P*QN==DG<;0,*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
K * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
